ACORDA THERAPEUTICS INC stock forecast: up to 2.66 USD ACOR stock price prognosis

STOCK

Forecast for Thu 27 Jan 2022 price 4.66

ACORDA THERAPEUTICS INC stock price forecast for further price development up to 5.41% (time horizon: 1 day) and price target of 2.66 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) ACORDA THERAPEUTICS INC share price prediction for 2022-01-27 with daily closed price projections

Key Facts

Symbol ACOR 

ISIN US00484M6012 

CUSIP 00484M601


Currency USD


Category Biological Products (No Diagnostic Substances)

Forecast price change %


News sentiment (-0.05)

Finance numbers

Revenue 153,730,000.0


Earnings per share -15.04


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

We also market branded Ampyra (dalfampridine) Extended Release Tablets, 10 mg. Net revenue for Inbrija was $24.2 million for the year ended December 31, 2020. This payment was recorded as milestone revenue in the third quarter. The COVID-19 pandemic has caused significant disruptions in the healthcare industry. Inbrija is for as needed use and utilizes our ARCUS platform for inhaled therapeutics. 8226; increased eye pressure in patients with glaucoma. This was demonstrated by an increase in walking speed. Fampyra has been approved in a number of countries across Europe, Asia and the Americas. We will vigorously defend our intellectual property rights. We completed these studies and timely submitted the results to the FDA. Civitas is required to use commercially reasonable efforts to develop ARCUS products. Any such interruptions in their ability to manufacture Inbrija would harm our business. Transition to a new inhaler supplier would be a lengthy and complex process. Ampyra/aminopyridines There are no patents listed in the Orange Book for Ampyra. Apokyn was approved for this use in the U.S. in 2004 and in Europe in 1993. Inbrija may face competition from therapies that can limit the occurrence of OFF periods. This therapy, known as Duopa, has been approved by the FDA and is approved in the EU. Many of these corticosteroids are available generically. This is known as a Special Protocol Assessment, or SPA. These fees could be significant. Instead, the FDA must make a separate finding of "interchangeability." The risks and uncertainties described below are not the only ones we face. The same risks apply to our other marketed products, such as Ampyra. In some cases, the penalties for failure to comply with these requirements are unclear. As of December 31, 2020, we had approximately $162.1 million of U.S. Federal NOLs.

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1008848/000156459021013318/0001564590-21-013318.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 17.36/100
    • Good financial position.
    • Historical view, profit is not growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
CANYON CAPITAL ADVISORS LLC 2021-03-31 196370
MILLENNIUM MANAGEMENT LLC 2021-03-31 35067
BRIDGEWAY CAPITAL MANAGEMENT, LLC 2021-03-31 70424
ROYAL BANK OF CANADA (RY, RY-PT, RYMTF) 2021-03-31 1076
Cutler Group LP 2021-06-30 117

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Concord Street Trust 2021-05-31 10397 Long
iShares U.S. ETF Trust 2021-04-30 185 Long
DFA INVESTMENT DIMENSIONS GROUP INC 2021-04-30 15849 Long
DFA INVESTMENT DIMENSIONS GROUP INC 2021-04-30 13216 Long
DFA INVESTMENT DIMENSIONS GROUP INC 2021-04-30 3453 Long

ACORDA THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.


On-Balance Volume information for ACORDA THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.


Accumulation / Distribution (A/D) indicator information for ACORDA THERAPEUTICS INC. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for ACORDA THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for ACORDA THERAPEUTICS INC. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for ACORDA THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for ACORDA THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for ACORDA THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


52W High 52W Low Market Cap

Similar shares


ACORDA THERAPEUTICS INC on Nasdaq

ACORDA THERAPEUTICS INC on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2021-12-03 2.66 2021-12-02 10:50
2021-12-06 2.82 2021-12-02 10:50
2021-12-07 2.95 2021-12-02 10:50
2021-12-08 3.05 2021-12-02 10:50
2021-12-09 3.16 2021-12-02 10:50
2021-12-10 3.26 2021-12-02 10:50
2021-12-13 3.38 2021-12-02 10:50
2021-12-14 3.48 2021-12-02 10:50
2021-12-15 3.57 2021-12-02 10:50
2021-12-16 3.67 2021-12-02 10:50
2021-12-17 3.77 2021-12-02 10:50
2021-12-20 3.83 2021-12-02 10:50
2021-12-21 3.87 2021-12-02 10:50
2021-12-22 3.90 2021-12-02 10:50
2021-12-23 3.93 2021-12-02 10:50
2021-12-24 3.97 2021-12-02 10:50
2021-12-27 4.00 2021-12-02 10:50
2021-12-28 4.02 2021-12-02 10:50
2021-12-29 4.03 2021-12-02 10:50
2021-12-30 4.06 2021-12-02 10:50
2021-12-31 4.09 2021-12-02 10:50
2022-01-03 4.12 2021-12-02 10:50
2022-01-04 4.15 2021-12-02 10:50
2022-01-05 4.18 2021-12-02 10:50
2022-01-06 4.22 2021-12-02 10:50
2022-01-07 4.26 2021-12-02 10:50
2022-01-10 4.29 2021-12-02 10:50
2022-01-11 4.32 2021-12-02 10:50
2022-01-12 4.36 2021-12-02 10:50
2022-01-13 4.39 2021-12-02 10:50
2022-01-14 4.43 2021-12-02 10:50
2022-01-17 4.46 2021-12-02 10:50
2022-01-18 4.49 2021-12-02 10:50
2022-01-19 4.51 2021-12-02 10:50
2022-01-20 4.54 2021-12-02 10:50
2022-01-21 4.57 2021-12-02 10:50
2022-01-24 4.59 2021-12-02 10:50
2022-01-25 4.61 2021-12-02 10:50
2022-01-26 4.64 2021-12-02 10:50
2022-01-27 4.66 2021-12-02 10:50